P. Chowdhury et al. / Steroids 70 (2005) 494–498
497
spectrum (m/z): 457 (M+). Anal. Calcd. for C27H39O5N:
C, 70.90; H, 8.53, N, 3.06; Found: C, 71.03; H, 8.66; N,
3.19.
OAc), 2.2 (bs, 6H, Me and COMe), 4.25 (m, 2H, H-3 and
H-16), 5.3 (m, 1H, H-6), 7.1–7.5 (m, 4H, Ph) ppm. Mass
spectrum (m/z): 489 (M+). Anal. Calcd. for C31H39O4N:
C, 76.07; H, 7.98; N, 2.86; Found: C, 76.19; H, 7.84,
N, 2.93.
1.2.1.11. 21-Hydroxy-3β-acetoxy-20-oxo-3ꢀ- (p-chlorobe-
nzo) isoxazolino [16,17-d] pregna-5-ene (2c). The reaction
of 21-chloro-16-dehydro-5, 6-dihydro pregnenolone acetate
2 with p-chlorobenzaldoxime c as per the general procedure
furnished the product 2c.
1.2.1.7. 3β-Acetoxy-20-oxo-3ꢀ-(4-nitro benzo) isoxazolino
[16,17-d] pregna-5-ene (1g). The reaction of 16-DPA 1 with
p-nitrobenzaldoxime g as per the general procedure furnished
the product 1g.
Mp: 139–141 ◦C; αD: (+)5◦ (C1, alc). IR (KBr): 3300,
Mp: 109–111 ◦C, αD: (−)108◦ (C1, CHCl3). IR (KBr):
1
1736, 1710, 1590, 1450, 1205 cm−1. H NMR (300 MHz,
1
1730, 1710, 1590, 1528, 1450, 1347, 1245, 855 cm−1. H
CDCl3): δ = 0.8 (s, 3H, Me), 1.0 (s, 3H, Me), 1.9 (s, 3H, OAc),
2.2 (s, 3H, COMe), 3.2 (d, J = 19 Hz, H-21), 3.6 (d, J = 19Hz,
H-21), 4.5 (m, 1H, H-3), 4.9 (m, 1H, H-16), 7.1–7.4 (m, 4H,
Ph) ppm. Mass spectrum (m/z): 527 (M+), 529 (M++2). Anal.
Calcd. for C30H38O5NCl(%): C, 68.31; H, 7.21; N, 2.66;
Found: C, 68.54; H, 7.39; N, 2.51.
NMR (300 MHz, CDCl3): δ = 0.9 (s, 3H, Me), 1.0 (s, 3H,
Me), 1.9 (s, 3H, OAc), 2.2 (s, 3H, COMe), 4.31 (m, 2H, H-
3 and H-16), 5.3 (m, 1H, H-6), 7.1–7.4 (m, 4H, Ph) ppm.
Mass spectrum (m/z): 520 (M+), 521 (M++1). Anal. Calcd.
for C30H36O6N2: C, 69.23; H, 6.92; N, 5.38; Found: C, 69.08;
H, 6.85, N, 5.23.
1.2.1.12. 21-Hydroxy-3β-acetoxy-20-oxo-3ꢀ- (phenyl ethy-
lene) isoxazolino [16,17-d] pregna-5-ene (2d). The reaction
of 21-chloro-16-dehydro-5, 6-dihydro pregnenolone acetate
2 with cinnamaldoxime d as per the general procedure fur-
nished the product 2d.
1.2.1.8. 3β-Acetoxy-20-oxo-3ꢀ-(n-heptyl) isoxazolino [16,
17-d] pregna-5-ene (1h). The reaction of 16-DPA 1 with
octanaldoxime h as per the general procedure furnished the
product 1h.
Mp: 224–226 ◦C, αD: (−)118◦ (C1, CHCl3). IR (KBr):
Mp: 248–250 ◦C, αD: (+)7◦ (C1, alc). IR (KBr): 3350,
1730, 1710, 1593, 1443, 121 cm−1 1H NMR (300 MHz,
.
1
1730, 1710, 1588, 1400, 1210 cm−1. H NMR (300 MHz,
CDCl3): δ = 0.9 (s, 3H, Me), 1.0 (s, 3H, Me), 1.9 (s, 3H,
OAc), 2.1 (s, 3H, COMe), 3.4 (m, 1H, H-16), 4.3 (m, 1H,
H-3), 5.3 (m, 1H, H-6) ppm. Mass spectrum (m/z): 497 (M+).
Anal. Calcd. for C31H47O4N: C, 74.85; H, 9.46; N, 2.82;
Found: C, 74.96; H, 9.54, N, 2.89.
CDCl3): δ = 0.9 (s, 3H, Me), 1.0 (s, 3H, Me), 1.9 (s, 3H,
OAc), 2.1 (s, 3H, COMe), 3.3 (d, J = 19 Hz, H-21), 3.6 (d,
J = 19Hz, H-21), 4.4 (m, 1H, H-3), 4.8 (m, 1H, H-16), 6.3
(m, 2H, –CH=CH–Ph), 7.1–7.4 (m, 5H, Ph) ppm. Mass
spectrum (m/z): 519 (M+). Anal. Calcd. for C32H41O5N:
C, 73.99; H, 7.90; N, 2.70; Found: C, 74.12; H, 7.77, N,
2.92.
1.2.1.9. 21-Hydroxy-3β-acetoxy-20-oxo-3ꢀ- (benzo) isoxa-
zolino [16,17-d] pregna-5-ene (2a). The reaction of 21-
chloro-16-dehydro-5, 6-dihydro pregnenolone acetate 2 with
benzaldoxime a as per the general procedure furnished the
product 2a.
1.2.1.13. 21-Hydroxy-3β-acetoxy-20-oxo-3ꢀ- (4-methoxyb-
enzo) isoxazolino [16,17-d] pregna-5-ene (2e). The reaction
of 21-chloro-16-dehydro-5, 6-dihydro pregnenolone acetate
2 with p-anisaldoxime e as per the general procedure fur-
nished the product 2e.
Mp: 212–214 ◦C, αD: (+)12◦ (C1, alc). IR (KBr):
1
3300, 1735, 1710, 1590, 1444, 1210, 800 cm−1. H NMR
Mp: 144–146 ◦C, αD: (+)3◦ (C1, alc). IR (KBr): 3305,
(300 MHz, CDCl3): δ = 0.9 (s, 3H, Me), 1.1 (s, 3H, Me), 1.9
(s, 3H, OAc), 2.2 (s, 3H, COMe), 3.4 (d, J = 19 Hz, H-21),
3.7 (d, J = 19 Hz, H-21), 4.4 (m, 1H, H-3), 4.9 (m, 1H, H-16),
7.1–7.4 (m, 5H, Ph) ppm. Mass spectrum (m/z): 493 (M+).
Anal. Cacld. for C30H39O5N: C, 73.02; H, 7.91; N, 2.84;
Found: C, 73.29; H, 7.61, N, 3.05.
1
1734, 1710, 1587, 1443, 1210 cm−1. H NMR (300 MHz,
CDCl3): δ = 0.9 (s, 3H, Me), 1.1 (s, 3H, Me), 1.9 (s, 3H,
OAc), 2.1 (s, 3H, COMe), 3.2–3.4 (m, 4H, H-21 and OMe),
3.6 (d, J = 19 Hz, H-21), 4.5 (m, 1H, H-3), 4.8 (m, 1H, H-16),
7.1–7.4 (m, 4H, Ph) ppm. Mass spectrum (m/z): 523 (M+).
Anal. Calcd. for C31H41O6N: C, 71.13; H, 7.84; N, 2.68;
Found: C, 71.34; H, 7.95, N, 2.75.
1.2.1.10. 21-Hydroxy-3β-acetoxy-20-oxo-3ꢀ- (prop-1-ene)
isoxazolino [16,17-d] pregna-5-ene (2b). The reaction of 21-
chloro-16-dehydro-5, 6-dihydro pregnenolone acetate 2 with
crotonaldoxime b as per the general procedure furnished the
product 2b.
1.2.1.14. 21-Hydroxy-3β-acetoxy-20-oxo-3ꢀ- (p-methylbe-
nzo) isoxazolino [16,17-d] pregna-5-ene (2f). The reaction
of 21-chloro-16-dehydro-5, 6-dihydro pregnenolone acetate
2 with p-tolualdoxime f as per the general procedure fur-
nished the product 2f.
Mp: 227–229 ◦C, αD: (+)11◦ (C1, alc). IR (KBr): 3303,
1
1734, 1710, 1590, 1445, 1210 cm−1. H NMR (300 MHz,
CDCl3): δ = 0.8 (s, 3H, Me), 1.1 (s, 3H, Me), 1.8 (s, 1H, Me
under double bond), 1.9 (s, 3H, OAc), 2.0 (s, 3H, COMe),
3.4 (d, J = 19 Hz, H-21), 3.7 (d, J = 19Hz, H-21), 3.9 (m, 1H,
H-16), 4.5 (m, 1H, H-3), 5.9 (m, 2H, –CH=CH–) ppm. Mass
Mp: 142–144 ◦C, αD: (+)8◦ (C1, alc). IR (KBr): 3300,
1
1735, 1710, 1589, 1445, 1200 cm−1. H NMR (300 MHz,
CDCl3): δ = 0.8 (s, 3H, Me), 1.1 (s, 3H, Me), 1.9 (s, 3H,
OAc), 2.2 (bs, 6H, Me and COMe), 3.4 (d, J = 19 Hz,